Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

Peter H. Wiernik, Izidore S. Lossos, Joseph M. Tuscano, Glen Justice, Julie M. Vose, Craig E. Cole, Wendy Lam, Kyle McBride, Kenton Wride, Dennis Pietronigro, Kenichi Takeshita, Annette Ervin-Haynes, Jerome B. Zeldis, Thomas Matthew Habermann

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Purpose: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results: Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%). Conclusion: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.

Original languageEnglish (US)
Pages (from-to)4952-4957
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number30
DOIs
StatePublished - Oct 20 2008

Fingerprint

Non-Hodgkin's Lymphoma
Neutropenia
Thrombocytopenia
Disease-Free Survival
Safety
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Leukopenia
Hematologic Neoplasms
lenalidomide
Multicenter Studies
Disease Progression
Cause of Death
Lymphoma
Histology
B-Lymphocytes
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., ... Habermann, T. M. (2008). Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26(30), 4952-4957. https://doi.org/10.1200/JCO.2007.15.3429

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. / Wiernik, Peter H.; Lossos, Izidore S.; Tuscano, Joseph M.; Justice, Glen; Vose, Julie M.; Cole, Craig E.; Lam, Wendy; McBride, Kyle; Wride, Kenton; Pietronigro, Dennis; Takeshita, Kenichi; Ervin-Haynes, Annette; Zeldis, Jerome B.; Habermann, Thomas Matthew.

In: Journal of Clinical Oncology, Vol. 26, No. 30, 20.10.2008, p. 4952-4957.

Research output: Contribution to journalArticle

Wiernik, PH, Lossos, IS, Tuscano, JM, Justice, G, Vose, JM, Cole, CE, Lam, W, McBride, K, Wride, K, Pietronigro, D, Takeshita, K, Ervin-Haynes, A, Zeldis, JB & Habermann, TM 2008, 'Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma', Journal of Clinical Oncology, vol. 26, no. 30, pp. 4952-4957. https://doi.org/10.1200/JCO.2007.15.3429
Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology. 2008 Oct 20;26(30):4952-4957. https://doi.org/10.1200/JCO.2007.15.3429
Wiernik, Peter H. ; Lossos, Izidore S. ; Tuscano, Joseph M. ; Justice, Glen ; Vose, Julie M. ; Cole, Craig E. ; Lam, Wendy ; McBride, Kyle ; Wride, Kenton ; Pietronigro, Dennis ; Takeshita, Kenichi ; Ervin-Haynes, Annette ; Zeldis, Jerome B. ; Habermann, Thomas Matthew. / Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 30. pp. 4952-4957.
@article{8a168401b2d74f8f867c25f6a38aea15,
title = "Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma",
abstract = "Purpose: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results: Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53{\%}), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35{\%} was observed in 49 treated patients, including a 12{\%} rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25{\%} improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2{\%}) and thrombocytopenia (8.2{\%}); the most common grade 3 adverse events were neutropenia (24.5{\%}), leukopenia (14.3{\%}), and thrombocytopenia (12.2{\%}). Conclusion: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.",
author = "Wiernik, {Peter H.} and Lossos, {Izidore S.} and Tuscano, {Joseph M.} and Glen Justice and Vose, {Julie M.} and Cole, {Craig E.} and Wendy Lam and Kyle McBride and Kenton Wride and Dennis Pietronigro and Kenichi Takeshita and Annette Ervin-Haynes and Zeldis, {Jerome B.} and Habermann, {Thomas Matthew}",
year = "2008",
month = "10",
day = "20",
doi = "10.1200/JCO.2007.15.3429",
language = "English (US)",
volume = "26",
pages = "4952--4957",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

AU - Wiernik, Peter H.

AU - Lossos, Izidore S.

AU - Tuscano, Joseph M.

AU - Justice, Glen

AU - Vose, Julie M.

AU - Cole, Craig E.

AU - Lam, Wendy

AU - McBride, Kyle

AU - Wride, Kenton

AU - Pietronigro, Dennis

AU - Takeshita, Kenichi

AU - Ervin-Haynes, Annette

AU - Zeldis, Jerome B.

AU - Habermann, Thomas Matthew

PY - 2008/10/20

Y1 - 2008/10/20

N2 - Purpose: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results: Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%). Conclusion: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.

AB - Purpose: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results: Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%). Conclusion: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.

UR - http://www.scopus.com/inward/record.url?scp=54449095901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449095901&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.3429

DO - 10.1200/JCO.2007.15.3429

M3 - Article

VL - 26

SP - 4952

EP - 4957

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -